Strides Pharma Science Limited

BSE:532531 Stock Report

Market Cap: ₹64.2b

Strides Pharma Science Past Earnings Performance

Past criteria checks 2/6

Strides Pharma Science's earnings have been declining at an average annual rate of -29.6%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 6.8% per year. Strides Pharma Science's return on equity is 7.8%, and it has net margins of 4%.

Key information

-29.6%

Earnings growth rate

-29.7%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate6.8%
Return on equity7.8%
Net Margin4.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Strides Pharma Science makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:532531 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2444,1031,7718,6750
30 Jun 2442,086-4757,9580
31 Mar 2440,511-1,2488,0340
31 Dec 2339,535-1,5257,6420
30 Sep 2337,806-2,2807,6070
30 Jun 2336,783-9247,1590
31 Mar 2336,884-2,2127,6860
31 Dec 2235,680-1,8247,3950
30 Sep 2234,976-2,2417,3850
30 Jun 2233,220-3,9096,6920
31 Mar 2230,703-4,6026,7280
31 Dec 2131,127-4,4256,6360
30 Sep 2131,504-2,8306,1200
30 Jun 2132,224-5435,8170
31 Mar 2133,1592,5455,7040
31 Dec 2030,260285,3590
30 Sep 2029,2645895,1920
30 Jun 2028,4801,2664,9060
31 Mar 2027,5204924,5790
31 Dec 1935,8282,8595,8720
30 Sep 1934,2032,1695,5360
30 Jun 1932,2487455,3460
31 Mar 1921,7848403,7070
31 Dec 1828,547-935,3490
30 Sep 1828,0901395,4200
30 Jun 1828,4514154,3630
31 Mar 1828,4515445,3340
31 Dec 1735,8101,0506,9210
30 Sep 1736,5931,1246,9310
30 Jun 1735,3571,7126,0640
31 Mar 1727,5542,3354,8600
31 Dec 1637,2372,8406,9840
30 Sep 1636,5732,4106,7600
30 Jun 1634,1892,1686,0610
31 Mar 1628,6221,3174,0260
31 Dec 1524,9011,1525,5080
30 Sep 1512,9628603,3670
30 Jun 1512,1052443,2060
31 Mar 1511,958161,9940
31 Mar 1410,728-1,8672,3290

Quality Earnings: 532531 has high quality earnings.

Growing Profit Margin: 532531 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 532531's earnings have declined by 29.6% per year over the past 5 years.

Accelerating Growth: 532531 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 532531 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).

Return on Equity

High ROE: 532531's Return on Equity (7.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 13:54
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Strides Pharma Science Limited is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aditya KhemkaAmbit Capital
Harith AhamedAvendus Spark
Prakash AgarwalAxis Capital Limited